{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:44:14Z","timestamp":1788349454866,"version":"build-2803163510"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>This was a 1-year prospective observational study of the health-related quality of life (HRQoL) of moderate to severe crohn's disease (CD) patients in Iran. Patients' HRQoL were measured using the EQ-5D 3L, EQ-VAS, and IBDQ-9 tools. HRQoL among CD patients were compared using the <jats:italic>T<\/jats:italic>-test, Mann\u2013Whitney, Chi-square, and Fisher's exact tests. To discover factors influencing patients' HRQoL, multivariate linear regression and multivariate logistic regression tests were utilized. The study included 222 CD patients, with a mean age of 34.67 and mean disease duration of 7.32 years. The dimensions with the worst reported \u201crelatively or extreme problems\u201d were P\/D: 77.5% and A\/D: 63.1%. Employment, having \u201cother chronic diseases,\u201d and ADA consumption were the most important independent predictors of HRQoL in CD patients, [\u03b2 = 0.21 (EQ-5D index), \u03b2 = 19.61 (EQ-VAS), \u03b2 = 12.26 (IBDQ-9), OR: 0.09 (MO), OR: 0.12 (UA), OR: 0.21 (P\/D), OR: 0.22 (A\/D)], [\u03b2 = \u22120.15 (EQ-5D index), \u03b2 = \u22125.84 (IBDQ-9), \u03b2 = \u221211.06 (EQ-VAS), OR: 4.20 (MO), OR: 6.50 (UA)], and [OR: 2.29 (A\/D)], respectively. Unemployment, presence of \u201cother chronic conditions\u201d had the greatest negative impact on HRQoL of CD patients. There were significant differences in the probability of reporting \u201crelatively or extreme problems\u201d in the SC and A\/D dimensions between patients using adalimumab (ADA) and infliximab (IFX).<\/jats:p>","DOI":"10.3389\/fmed.2022.1091330","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T07:17:48Z","timestamp":1674112668000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Factors associated with health-related quality of life in patients with Crohn's disease in Iran: A prospective observational study"],"prefix":"10.3389","volume":"9","author":[{"given":"Hassan","family":"Karami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Shirvani Shiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farbod","family":"Ebadi Fard Azar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Bagheri Lankarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulmaz","family":"Ghahramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Rezapour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Tatari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Heidari Javargi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1590\/s0004-2803.201800000-26","article-title":"Symptoms of anxiety and depression, and quality of life of patients with Crohn's disease","volume":"55","author":"Tomazoni","year":"2018","journal-title":"Arq Gastroenterol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/0016-5085(79)90389-5","article-title":"Clinical features and natural history of Crohn's disease","volume":"77","author":"Mekhjian","year":"1979","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1097\/MCG.0000000000000660","article-title":"World gastroenterology organisation global guidelines inflammatory bowel disease: update august 2015","volume":"50","author":"Bernstein","year":"2016","journal-title":"J Clin Gastroenterol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"CD012973","DOI":"10.1002\/14651858.CD012973","article-title":"The impact of biological interventions on health-related quality of life in adults with Crohn's disease","volume":"2018","author":"Stanic Benic","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1046\/j.1365-2036.2002.01323.x","article-title":"The quality of life in patients with Crohn's disease","volume":"16","author":"Cohen","year":"2002","journal-title":"Aliment Pharmacol Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1365-2036.2005.02380.x","article-title":"Review article: psychosocial factors in the quality of life of patients with inflammatory bowel disease","volume":"21","author":"Sainsbury","year":"2005","journal-title":"Aliment Pharmacol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1097\/00042737-200412000-00007","article-title":"Predictors of disease-related concerns and other aspects of health-related quality of life in outpatients with inflammatory bowel disease","volume":"16","author":"Mussell","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.cgh.2006.09.027","article-title":"The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life","volume":"4","author":"Graff","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.crohns.2013.04.007","article-title":"Determinants of health-related quality of life in Crohn's disease: a systematic review and meta-analysis","volume":"8","author":"Van der have","year":"2014","journal-title":"J Crohns Colitis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1111\/j.1572-0241.2008.02175.x","article-title":"Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the charm trial","volume":"103","author":"Loftus","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.crohns.2012.01.019","article-title":"Restoration of quality of life of patients with inflammatory bowel disease after one year with antitnf\u03b1 treatment","volume":"6","author":"Casellas","year":"2012","journal-title":"J Crohns Colitis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1111\/j.1572-0241.2001.03878.x","article-title":"Cross-cultural variation in disease-related concerns among patients with inflammatory bowel disease","volume":"96","author":"Levenstein","year":"2001","journal-title":"Am J Gastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/003655201300051171","article-title":"Impaired health-related quality of life in inflammatory bowel diseases psychosocial impact and coping styles in a national German sample","volume":"36","author":"Petrak","year":"2001","journal-title":"Scand J Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5812\/acr.11477","article-title":"Epidemiology of inflammatory bowel diseases (IBD) in Iran: a review of 740 patients in Fars province, southern Iran","volume":"1","author":"Taghavi","year":"2013","journal-title":"Iran J Colorectal Res."},{"key":"B15","first-page":"140","article-title":"Epidemiology of inflammatory bowel diseases in Iran and Asia; a mini review","volume":"38","author":"Safarpour","year":"2013","journal-title":"Iran J Med Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.vhri.2019.01.007","article-title":"Valuation of quality weights for euroqol 5-dimensional health states with the time trade-off method in the capital of Iran","volume":"18","author":"Goudarzi","year":"2019","journal-title":"Value Health Reg Issues."},{"key":"B17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.dsx.2021.01.009","article-title":"Validity and reliability of the eq-5d-3l (a generic preference-based instrument used for calculating quality-adjusted life -years) for patients with type 2 diabetes in Iran","volume":"15","author":"Zare","year":"2021","journal-title":"Diabetes Metab Syndr."},{"key":"B19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1572-0241.2004.04071.x","article-title":"Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire","volume":"99","author":"Casellas","year":"2004","journal-title":"Am J Gastroenterol."},{"key":"B20","first-page":"1","article-title":"Linguistic validation of the inflammatory bowel disease questionnaire-short form (IBDQ-9) in Iranian population","volume":"28","author":"Gholamrezaei","year":"2011","journal-title":"J Isfahan Med Sch"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/j.1365-2036.2009.03966.x","article-title":"Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the sf-36 and the eq-5d vas in patients with active Crohn's disease","volume":"29","author":"Coteur","year":"2009","journal-title":"Aliment Pharmacol Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ibd.20989","article-title":"Validity, reliability, and responsiveness of the eq-5d in inflammatory bowel disease in Germany","volume":"16","author":"Stark","year":"2009","journal-title":"Inflamm Bowel Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.crohns.2010.07.006","article-title":"Cutoff values of the inflammatory bowel disease questionnaire to predict a normal health related quality of life?","volume":"4","author":"Huam\u00e1n","year":"2010","journal-title":"J Crohns Colitis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e11602","DOI":"10.2196\/11602","article-title":"A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial","volume":"20","author":"Del Hoyo","year":"2018","journal-title":"J Med Internet Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s11136-021-02792-7","article-title":"The association between diabetic complications and health-related quality of life in patients with type 2 diabetes: a cross-sectional study from Iran","volume":"30","author":"Karami","year":"2021","journal-title":"Qual Life Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"733","DOI":"10.15171\/ijhpm.2015.113","article-title":"Comparison of blood transfusion plus chelation therapy and bone marrow transplantation in patients with \u03b2-thalassemia: application of sf-36, eq-5d, and visual analogue scale measures","volume":"4","author":"Javanbakht","year":"2015","journal-title":"Int J Health Policy Manag."},{"key":"B27","article-title":"Adalimumab versus infliximab treatment outcome in ulcerative colitis: application of eq-5d, visual analogue scale, and ibdq-9 measures: a prospective observational study","author":"Karami","year":"2022","journal-title":"Curr Drug Saf."},{"key":"B28","first-page":"153","article-title":"Health status and quality of life in patients with psoriasis: an Iranian cross-sectional survey","volume":"18","author":"Moradi","year":"2015","journal-title":"Arch Iran Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/07357907.2021.1992632","article-title":"Utility values in colorectal cancer patients treated with chemotherapy","volume":"40","author":"Atfannezhad","year":"2022","journal-title":"Cancer Invest."},{"key":"B30","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/01.mib.0000179467.01748.99","article-title":"Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms","volume":"11","author":"Bernklev","year":"2005","journal-title":"Inflamm Bowel Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1080\/003655202317316097","article-title":"Health-related quality of life and psychological distress in a population-based sample of swedish patients with inflammatory bowel disease","volume":"37","author":"Nordin","year":"2002","journal-title":"Scand J Gastroenterol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.3748\/wjg.v16.i25.3168","article-title":"Impact of pain on health-related quality of life in patients with inflammatory bowel disease","volume":"16","author":"Schirbel","year":"2010","journal-title":"World j Gastroenterol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1007\/s10620-017-4874-6","article-title":"Comparative effectiveness of infliximab versus adalimumab in patients with biologic-na\u00efve Crohn's disease","volume":"63","author":"Benmassaoud","year":"2018","journal-title":"Dig Dis Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/imj.13040","article-title":"retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease","volume":"46","author":"Varma","year":"2016","journal-title":"Intern Med J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/apt.13671","article-title":"The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-\u03b1 na\u00efve Crohn's disease","volume":"44","author":"Narula","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.cgh.2013.01.012","article-title":"Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti\u2013tumor necrosis factor-\u03b1 agents","volume":"11","author":"Kestens","year":"2013","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2147\/CLEP.S150030","article-title":"Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease","volume":"10","author":"Di domenicantonio","year":"2018","journal-title":"Clin Epidemiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ejim.2014.02.010","article-title":"Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres","volume":"25","author":"Tursi","year":"2014","journal-title":"Eur J Intern Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1590\/S0004-28032014000300005","article-title":"Castro FDd, Carvalho PB, Moreira MJ, Cotter J. Quality of life in patients with inflammatory bowel disease: importance of clinical, demographic and psychosocial factors","volume":"51","author":"Magalh\u00e3es","year":"2014","journal-title":"Arq de Gastroenterol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1080\/13696998.2020.1791889","article-title":"The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia","volume":"23","author":"AlRuthia","year":"2020","journal-title":"J Med Econ."},{"key":"B41","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.crohns.2011.10.001","article-title":"patients with Crohn's disease experience reduced general health and vitality in the chronic stage: ten-year results from the Ibsen study?","volume":"6","author":"H\u00f8ivik","year":"2012","journal-title":"J Crohns Colitis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/ecco-jcc\/jjw145","article-title":"Patient-reported outcomes in a French nationwide survey of inflammatory bowel disease patients","volume":"11","author":"Williet","year":"2016","journal-title":"J Crohns Colitis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1097\/MIB.0000000000000806","article-title":"Health-related quality of life in patients with inflammatory bowel disease 20 years after diagnosis: results from the Ibsen study","volume":"22","author":"Huppertz-hauss","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1097\/MEG.0000000000000666","article-title":"Effect of psychosocial stressors on patients with Crohn's disease: threatening life experiences and family relations","volume":"28","author":"Slonim-nevo","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"5862","DOI":"10.3748\/wjg.v25.i38.5862","article-title":"Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil","volume":"25","author":"Parra","year":"2019","journal-title":"World J Gastroenterol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4103\/jrms.JRMS_975_16","article-title":"quality of life in inflammatory bowel disease patients: a cross-sectional study","volume":"22","author":"Habibi","year":"2017","journal-title":"J Res Med Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/01.MIB.0000191670.04605.e7","article-title":"Impact of chronic conditions on quality of life in patients with inflammatory bowel disease","volume":"12","author":"Pizzi","year":"2006","journal-title":"Inflamm Bowel Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/MEG.0000000000000685","article-title":"Employment status, difficulties at work and quality of life in inflammatory bowel disease patients","volume":"28","author":"De Boer","year":"2016","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/01.MIB.0000218762.61217.4a","article-title":"Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease","volume":"12","author":"Bernklev","year":"2006","journal-title":"Inflamm Bowel Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/SGA.0000000000000491","article-title":"Health-related quality of life among patients with inflammatory bowel disease: a case control study","volume":"44","author":"Kamp","year":"2021","journal-title":"Gastroenterol Nurs."},{"key":"B51","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/ecco-jcc\/jjw160","article-title":"Smoking is associated with higher disease-related costs and lower health-related quality of life in inflammatory bowel disease","volume":"11","author":"Severs","year":"2016","journal-title":"J Crohns Colitis."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1091330\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T14:34:26Z","timestamp":1674657266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1091330\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":51,"alternative-id":["10.3389\/fmed.2022.1091330"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1091330","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]},"article-number":"1091330"}}